These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 36069496

  • 1. The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy.
    Seervai RNH, Friske SK, Chu EY, Phillips R, Nelson KC, Huen A, Cho WC, Aung PP, Torres-Cabala CA, Prieto VG, Curry JL.
    J Cutan Pathol; 2023 Jan; 50(1):72-95. PubMed ID: 36069496
    [Abstract] [Full Text] [Related]

  • 2. Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy.
    Seervai RNH, Cho WC, Chu EY, Marques-Piubelli ML, Ledesma DA, Richards K, Heberton MM, Nelson KC, Nagarajan P, Torres-Cabala CA, Prieto VG, Curry JL.
    J Cutan Pathol; 2022 Jan; 49(1):61-81. PubMed ID: 34622477
    [Abstract] [Full Text] [Related]

  • 3. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
    Chen WS, Tetzlaff MT, Diwan H, Jahan-Tigh R, Diab A, Nelson K, Glitza IC, Kaunitz GJ, Johnson D, Torres-Cabala C, Pacha O, Taube JM, Maloney K, Prieto VG, Curry JL.
    J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J.
    BMJ; 2018 Nov 08; 363():k4226. PubMed ID: 30409774
    [Abstract] [Full Text] [Related]

  • 6. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, Segura S, Freites-Martinez A, Lallas K, Romano MC, Oikonomou C, Starace M, Dimopoulos MA, Kyrgidis A, Lazaridou E, Giavedoni P, Annunziata MC, Peris K, Echeverría M, Lopez-Tujillo E, Syrigos K, Papageorgiou C, Podlipnik S, Fabbrocini G, Torre AC, Kemanetzi C, Villa-Crespo L, Lallas A, Stratigos AJ, Sibaud V.
    Br J Dermatol; 2022 Dec 08; 187(6):962-969. PubMed ID: 35861701
    [Abstract] [Full Text] [Related]

  • 7. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V.
    Am J Clin Dermatol; 2018 Jun 08; 19(3):345-361. PubMed ID: 29256113
    [Abstract] [Full Text] [Related]

  • 8. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL.
    Am J Dermatopathol; 2017 Feb 08; 39(2):121-129. PubMed ID: 28134729
    [Abstract] [Full Text] [Related]

  • 9. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E.
    Clin Colorectal Cancer; 2018 Jun 08; 17(2):85-96. PubMed ID: 29576427
    [Abstract] [Full Text] [Related]

  • 10. Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:: The Era of Oncodermatopathology.
    Curry JL, Chon SY, Marques-Piubelli ML, Chu EY.
    Surg Pathol Clin; 2021 Jun 08; 14(2):209-224. PubMed ID: 34023101
    [Abstract] [Full Text] [Related]

  • 11. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.
    Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL.
    J Cutan Pathol; 2019 Nov 08; 46(11):872-877. PubMed ID: 31254410
    [Abstract] [Full Text] [Related]

  • 12. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
    Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL.
    J Cutan Pathol; 2016 Aug 08; 43(8):688-96. PubMed ID: 27086658
    [Abstract] [Full Text] [Related]

  • 13. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
    Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, Sassier M, Plane AF, Comoz F, Cohen AA, Thuny FR, Cautela J, Alexandre J.
    J Immunother Cancer; 2020 Jan 08; 8(1):. PubMed ID: 31988143
    [Abstract] [Full Text] [Related]

  • 14. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
    Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG.
    J Cutan Pathol; 2017 Feb 08; 44(2):158-176. PubMed ID: 27859479
    [Abstract] [Full Text] [Related]

  • 15. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME.
    J Am Acad Dermatol; 2020 Nov 08; 83(5):1255-1268. PubMed ID: 32454097
    [Abstract] [Full Text] [Related]

  • 16. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH, Yu HS, Yu S.
    Curr Oncol; 2022 Apr 18; 29(4):2871-2886. PubMed ID: 35448208
    [Abstract] [Full Text] [Related]

  • 17. Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review.
    Liu LY, Teng JMC, Spunt SL, Strelo JL, Kwong BY, Zaba LC.
    Pediatr Blood Cancer; 2021 Dec 18; 68(12):e29346. PubMed ID: 34569142
    [Abstract] [Full Text] [Related]

  • 18. Central nervous system complications associated with immune checkpoint inhibitors.
    Vogrig A, Muñiz-Castrillo S, Joubert B, Picard G, Rogemond V, Marchal C, Chiappa AM, Chanson E, Skowron F, Leblanc A, Ducray F, Honnorat J.
    J Neurol Neurosurg Psychiatry; 2020 Jul 18; 91(7):772-778. PubMed ID: 32312871
    [Abstract] [Full Text] [Related]

  • 19. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS.
    J Am Acad Dermatol; 2018 Dec 18; 79(6):1047-1052. PubMed ID: 29857011
    [Abstract] [Full Text] [Related]

  • 20. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV.
    J Cutan Med Surg; 2021 Dec 18; 25(1):59-76. PubMed ID: 32746624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.